Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Oncology

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2007.11.8109PMID 17761978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

  2007cited by this paper
• A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

  2005cited by this paper
• Low‐dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

  2005cited by this paper
• Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.

  2005cited by this paper
• Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.

  2005cited by this paper
• Management of small-cell lung cancer.

  2004cited by this paper
• Targeted molecules in small cell lung cancer.

  2004cited by this paper
• Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer

  2002cited by this paper
• A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies

  2002cited by this paper
• A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC)

  2002cited by this paper
• Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.

  2001cited by this paper
• Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

  2000cited by this paper
• Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer

  2000cited by this paper
• Antitumor activity of thalidomide in refractory multiple myeloma.

  1999cited by this paper
• Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

  1998cited by this paper
• Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre

  1998cited by this paper
• Interferon Maintenance Therapy for Small Cell Lung Cancer: Improvement in Long-Term Survival

  1997cited by this paper
• Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.

  1997cited by this paper
• Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group.

  1997cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.

  1994cited by this paper
• Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.

  1994cited by this paper
• Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.

  1993cited by this paper
• Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma.

  1993cited by this paper
• The calculation of received dose intensity.

  1990cited by this paper
• Duration of chemotherapy in small cell lung cancer.

  1990cited by this paper
• Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.

  1989cited by this paper
• Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients

  1987cited by this paper
• Causes of treatment failure and death in carcinoma of the lung.

  1981cited by this paper
• Keynote address on biostatistics and data retrieval.

  1973cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer.

  2025cites this paper
• Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

  2024cites this paper
• Clinical Benefits of new Systemic Therapy for Small‐Cell Lung Cancer Over Two Decades: A Cross‐Sectional Study

  2024cites this paper
• Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis

  2022cites this paper
• Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis

  2021cites this paper
• Angiogenesis Inhibitors in Small Cell Lung Cancer

  2021cites this paper
• Development and Validation of a Simplified Prognostic Score in SCLC

  2020cites this paper
• Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer

  2020cites this paper
• A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.

  2020cites this paper
• Prognostic significance of IFITM1 expression and correlation with microvessel density and epithelial-mesenchymal transition signature in lung adenocarcinoma.

  2019cites this paper
• Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer

  2019cites this paper
• Inflammasome inhibitors: promising therapeutic approaches against cancer

  2019cites this paper
• The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer

  2019cites this paper
• Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study

  2019cites this paper
• Could WNT inhibitors really knock on the treatment door of small cell lung cancer?

  2019cites this paper
• Chemotherapy for Small Cell Lung Cancer 58

  2018cites this paper
• Novel carbonic anhydrase IX‐targeted therapy enhances the anti‐tumour effects of cisplatin in small cell lung cancer

  2018cites this paper
• Current and future therapeutic approaches for the treatment of small cell lung cancer

  2018cites this paper
• Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC)

  2018cites this paper
• Chemotherapy for Small Cell Lung Cancer 58

  2018cites this paper
• Progress and challenges in the treatment of small cell lung cancer

  2017cites this paper
• The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine.

  2017cites this paper
• A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113

  2017cites this paper
• Bevacizumab in advanced lung cancer: state of the art.

  2017cites this paper
• Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

  2017cites this paper
• Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer

  2017cites this paper
• Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.

  2017cites this paper
• Recent Advances and Future Strategies for Immune‐Checkpoint Inhibition in Small‐Cell Lung Cancer

  2017cites this paper
• Elusive Target of Angiogenesis in Small-Cell Lung Cancer.

  2017cites this paper
• Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC)

  2017cites this paper
• Advances in antiangiogenic treatment of small-cell lung cancer

  2017cites this paper
• Small Cell Lung Cancer and Molecular Targeted Therapy

  2017cites this paper
• Targeting angiogenesis in small cell lung cancer.

  2016cites this paper
• Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC

  2016cites this paper
• Personalized Therapy of Small Cell Lung Cancer.

  2016cites this paper
• Targeted drugs in small-cell lung cancer.

  2016cites this paper
• Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer

  2016cites this paper
• Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

  2016cites this paper
• No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.

  2016cites this paper
• Anti-angiogenesis in Personalized Therapy of Lung Cancer.

  2016cites this paper
• Évaluation de la chimiothérapie en 2e ligne du cancer bronchique à petites cellules entre 2004 et 2014 en Picardie

  2016cites this paper
• Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

  2016cites this paper
• Management of Small Cell Lung Cancer: Progress and Updates

  2015cites this paper
• Correlation of Perfusion MRI and 18F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation

  2015cites this paper
• Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

  2015cites this paper
• Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

  2015cites this paper
• Genomic profiling of small-cell lung cancer: the era of targeted therapies.

  2015cites this paper
• Can we expect progress from targeted therapy of SCLC

  2015cites this paper
• Targeted therapies for small cell lung cancer: Where do we stand?

  2015cites this paper
• Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  2014cites this paper
• Cancer bronchique à petites cellules stade étendu

  2014cites this paper
• Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer

  2014cites this paper
• Treatment of small cell lung cancer.

  2014cites this paper
• Schedule-dependent Interactions between Pemetrexed and Vinorelbine in Human Lung Cancer Cells

  2014cites this paper
• Progress in the management of limited‐stage small cell lung cancer

  2014cites this paper
• Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy

  2014cites this paper
• Advances in pharmacotherapy of small cell lung cancer

  2014cites this paper
• Cancers bronchiques à petites cellules étendus Traitement standard et nouvelles approches thérapeutiques

  2014cites this paper
• Do anti-angiogenic cancer therapies increase risk of significant weight loss?

  2014cites this paper
• Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.

  2013cites this paper
• Overview of recent translational research of small-cell lung cancer (SCLC) Ongoing translational research has focused on the following targeted drugs: angiogenesis inhibitors, matrix metalloproteinase (MMP) inhibitors, mTOR inhibitors, c-kit inhibitors, Bcl-2 antagonists, topoisomerase inhibitors, a

  2013cites this paper
• Medical treatment of small cell lung cancer: state of the art and new development

  2013cites this paper
• Cancer Therapy : Preclinical The Janus Kinases Inhibitor AZD 1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo

  2013cites this paper
• Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2013cites this paper
• Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.

  2013cites this paper
• Breakthrough expected in translational research of targeted therapy for small cell lung cancer.

  2013cites this paper
• A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer

  2013cites this paper
• Systemic therapy for small cell lung cancer.

  2013cites this paper
• Les cancers bronchiques à petites cellules

  2013cites this paper
• Small-cell lung cancer: an update on targeted therapies.

  2013cites this paper
• Targeted therapy and new anticancer drugs in advanced disease.

  2013cites this paper
• The development of targeted therapy in small cell lung cancer.

  2013cites this paper
• Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen

  2013cites this paper
• Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2013cites this paper
• Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches

  2013cites this paper
• The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo

  2013cites this paper
• [Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities].

  2012cites this paper
• Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.

  2012cites this paper
• Traitement des cancers bronchiques à petites cellules métastatiques en 2012

  2012cites this paper
• Les antiangiogéniques : limites actuelles en oncologie thoracique

  2012cites this paper
• The application and biology of immunomodulatory drugs (IMiDs) in cancer.

  2012cites this paper
• Modern Management of Small-Cell Lung Cancer

  2012cites this paper
• [Antiangiogenic agents: current limits in thoracic oncology].

  2012cites this paper
• Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.

  2012cites this paper
• Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide

  2012cites this paper
• The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.

  2012cites this paper
• Targeted therapies in small cell lung cancer.

  2012cites this paper
• Maintenance therapy in solid tumors

  2012cites this paper
• Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study.

  2012cites this paper
• Traitements anti-angiogéniques en pratique et dans le futur en oncologie thoracique

  2012cites this paper
• Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.

  2011cites this paper
• Novel strategies for the treatment of small-cell lung carcinoma

  2011cites this paper
• [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].

  2011cites this paper
• Targeted therapies in malignant pleural mesothelioma: a review of clinical studies

  2011cites this paper
• Small cell lung cancer: new clinical recommendations and current status of biomarker assessment.

  2011cites this paper
• The Enhancement of Radiosensitivity in Human Esophageal Carcinoma Cells by Thalidomide and Its Potential Mechanism

  2011cites this paper
• Update on new drugs in small cell lung cancer

  2011cites this paper
• SySteMic therapy fOr nOn-SMall cell lung cancer in 2011 Multiple options are linked to improved survival and quality of life

  2011cites this paper
• Small Cell Lung Cancer: Patterns of care and their influence on survival – 25 years experience of a single Australian oncology unit

  2011cites this paper
• Emerging treatments for small-cell lung cancer: Phase II and III trials

  2011cites this paper